title: Hepatic cysts treated with percutaneous ethanol sclerotherapy: time to extend the indications to haemorrhagic cysts and polycystic liver disease.
abstract: OBJECTIVE
  To describe the long-term clinical and morphological outcome of symptomatic hepatic cysts treated with percutaneous ethanol sclerotherapy (PES).
  
  
  METHODS
  From December 2003 to September 2011, all patients with hepatic cysts undergoing PES with a follow-up after 12 months were included. Evolution of the volume of the cysts and clinical and biological data were recorded. Features of the cyst were evaluated in each patient: simple, haemorrhagic or developed on underlying polycystic liver disease (PCLD).
  
  
  RESULTS
  Fifty-eight cysts (median volume 666 mL) were treated in 57 patients (52 women, mean age 58 years (18-80)). Twenty-two patients (39 %) had simple hepatic cysts, 19 (33 %) had dominant cysts on PCLD and 20 had haemorrhagic cysts (34.5 %), including 4 with PCLD. After a mean 27.3 months of follow-up, the final median cystic volume was 13.5 mL (p < 0.0001), and the median reduction in cyst volume was 94 % (58-100 %). Treatment was satisfactory in 95 % of the patients (54/57) (symptoms disappeared in 45/57 (79 %), decreased in 9/57 (16 %)). There was no clinical or morphological difference between patients with PCLD, haemorrhagic cysts or simple cysts.
  
  
  CONCLUSIONS
  The clinical and morphological efficacy of a single session of PES is very high, regardless of the presence of intracystic haemorrhage or underlying PCLD.
  
  
  CONCLUSIONS
  • The clinical efficacy of percutaneous ethanol sclerotherapy is very high. • Haemorrhagic content should not be a contraindication for percutaneous sclerotherapy. • Dominant cysts on polycystic liver disease should be treated with PES. • Imaging follow-up should not be performed shortly after the procedure.
authors.affiliation: Department of Radiology, University Hospitals Paris Nord Val de Seine, Beaujon, Clichy, Hauts-de-Seine, France.
authors.forename: Julie
authors.initials: J
authors.lastname: Benzimra
authors.forename: Maxime
authors.initials: M
authors.lastname: Ronot
authors.forename: David
authors.initials: D
authors.lastname: Fuks
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abdel-Rehim
authors.forename: Annie
authors.initials: A
authors.lastname: Sibert
authors.forename: Olivier
authors.initials: O
authors.lastname: Farges
authors.forename: Valérie
authors.initials: V
authors.lastname: Vilgrain
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003560:Cysts / Q000000981:diagnostic imaging / Q000628:therapy*; D000431:Ethanol / Q000627:therapeutic use*; D005260:Female; D006474:Hemorrhagic Disorders / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D008107:Liver Diseases / Q000000981:diagnostic imaging / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D061330:Multidetector Computed Tomography; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D012597:Sclerosing Solutions; D000431:Ethanol